Landing
European Society of Retina Specialists (EURETINA) 2024
AI-based qOCT analysis of Phase-III trials OAKS & DERBY data on the effect of Pegcetacoplan on Geographic Atrophy
Monitoring treatment efficacy of GA secondary to AMD using AI-prediction and assessment of intra-individual fellow eye predictors
Beneficial Effects in Macular Function with Continuous Pegcetacoplan Treatment: OAKS, DERBY, and GALE Open-Label Extension
A deep-learning approach to identifying quantitative OCT biomarkers predictive of visual deficit measured by microperimetry at 24 months in the OAKS trial
Pegcetacoplan for Geographic Atrophy: Update on Clinical Studies and Real-world Experience
SD-OCT and Fundus Autofluorescence in geographic atrophy: a comprehensive point-to-point correlation of FAF and SD-OCT using the phase III DERBY and OAKS trials
Mental Health and Loss of Independence in Geographic Atrophy: Results From the Large Global MOSAIC Study Among Patients and Their Caregivers in Australia, Canada, and Europe
Pegcetacoplan vs Avacincaptad Pegol in Geographic Atrophy: An Anchored Matching-Adjusted Indirect Comparison of Three Phase 3 Trials Over 24 Months
Repeatability and Reproducibility of a Novel Methodology for the Assessment of Visual Function Changes on Microperimetry in High-Risk Areas of the Retina in Patients with Treated Geographic Atrophy Secondary to Age-Related Macular Degeneration
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.